Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

146.03 +0.03 (+0.02%)

Streaming Delayed Price Updated: 3:24 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

72 73 Next >

7 Defensive Stocks to Buy as Investors Seek Shelter ↗

August 14, 2024

With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks.

Via InvestorPlace

3 Stocks Retirees Should Absolutely Love ↗

August 10, 2024

All of these stocks can provide steady income to retired investors.

Via The Motley Fool

Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels ↗

August 09, 2024

Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by...

Via Benzinga

Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday? ↗

August 09, 2024

After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic...

Via Benzinga

Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat ↗

August 08, 2024

The company retained its full-year outlook for product sales.

Via Investor's Business Daily

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

August 06, 2024

Via Benzinga

Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

GILD earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Gilead Sciences Announces Second Quarter 2024 Financial Results

August 08, 2024

From Gilead Sciences, Inc.

Via Business Wire

Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until... ↗

August 08, 2024

U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims...

Via Benzinga

Topics Economy Stocks

Gilead Sciences's Options Frenzy: What You Need to Know ↗

July 30, 2024

Via Benzinga

Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday? ↗

August 08, 2024

Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the...

Via Benzinga

Four Stocks To Watch This Week - Monday, August 5 ↗

August 05, 2024

The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will...

Via Talk Markets

$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

July 29, 2024

Via Benzinga

This Is What Whales Are Betting On Gilead Sciences ↗

July 25, 2024

Via Benzinga

2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off ↗

August 03, 2024

Dividend stocks are great; cheap dividend stocks are better.

Via The Motley Fool

Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List ↗

August 02, 2024

Traders are rushing out of overvalued and overhyped Nasdaq stocks, making it a great time to rotate into these Nasdaq stocks to watch.

Via InvestorPlace

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

August 02, 2024

The Stock Whisper Index provides a weekly list of five stocks that are seeing above-average interest from readers.

Via Benzinga

The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗

July 31, 2024

These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects.

Via InvestorPlace

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗

July 31, 2024

Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.

Via InvestorPlace

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields ↗

July 29, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 26, 2024

Via Benzinga

Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On ↗

July 25, 2024

Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing prices, it dropped 4.7% in 2 sessions.

Via Benzinga

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 25, 2024

From Gilead Sciences, Inc.

Via Business Wire

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

July 25, 2024

From Gilead Sciences, Inc.

Via Business Wire

3 Stocks That Can Help You to Get Richer in 2024 and Beyond ↗

July 25, 2024

Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.

Via The Motley Fool

Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price ↗

July 24, 2024

Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggesting it could be produced for $40. Campaigners are urging for global price...

Via Benzinga

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

July 24, 2024

From Gilead Sciences, Inc.

Via Business Wire

Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial ↗

July 23, 2024

ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...

Via Benzinga

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst ↗

July 22, 2024

HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.